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Total antioxidant capacity is associated
with mortality of patients with severe
traumatic brain injury
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Abstract
Background: Previously, circulating total antioxidant capacity (TAC) in traumatic brain injury (TBI) patients has been
scarcely studied and only in studies of small sample size (lower than 55 TBI patients). In one study were found
higher serum TAC in non-survivor than in survivor TBI patients; however, an association between circulating TAC
and mortality in patients with TBI has not been previously reported. Thus, the objective of this study was to
determine whether there is an association between circulating TAC, peroxidation state and mortality in patients
with severe TBI.
Methods: This was a multicenter, observational and prospective study was carried out in six Spanish Intensive Care
Units. We included patients with severe TBI defined as Glasgow Coma Scale (GCS) lower than 9. We excluded
patients with Injury Severity Score (ISS) in non-cranial aspects higher than 9. We measured serum TAC on day 1 of
TBI. The 30-day mortality was established as endpoint.
Results: Non-surviving TBI patients (N = 27) showed higher serum TAC (P < 0.001) than survivor ones (N = 73).
Logistic regression analyses showed that serum TAC higher than 2.59 nmol/mL were associated with 30-day
mortality controlling for APACHE-II and CT classification (OR = 4.40; 95 % CI = 1.14–16.98; P = 0.03), controlling for
GCS and age (OR = 5.88; 95 % CI = 1.57–22.06; P = 0.009), and controlling for CT classification and admission
abnormal pupils (OR = 3.89; 95 % CI = 1.30–11.61; P = 0.02). There was an association between serum TAC and
malondialdehyde (a biomarker of lipid peroxidation) levels (rho = 0.25; p = 0.01), APACHE-II score (rho = 0.23; p = 0.03)
and GCS (rho = −0.21; p = 0.04).
Conclusions: To our knowledge, our series is the largest reporting data on circulating TAC in patients with severe TBI.
The most relevant and new findings of our study were that there is an association between circulating TAC and
peroxidation state and mortality in patients with severe TBI.
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Background
Traumatic brain injury (TBI) could leads to death, disabil-
ity, and high resources consume [1]. TBI causes two kinds
of injury in the brain: 1) Primary injury, which appears at
moment of the impact and is due to the initial physical
forces applied to brain; 2) Secondary injury, which appears
in the following hours or days, and leads to neuroinflam-
matory response and free radical generation [2].
Reactive oxygen species (ROS) are produced after TBI
and they are involved in the secondary brain injury [3–6].
Under physiologic conditions, ROS are carefully balanced
by the action of antioxidant defenses in cerebral tissue.
These antioxidants do not work alone but they establish
complex interactions with each others [7]. Thus, measure-
ment of total antioxidant capacity (TAC) in serum or
plasma, may give more biologically relevant information
about patient antioxidant status than that obtained from
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measuring concentrations of individual compounds [8].
However, when antioxidant defenses are overwhelmed,
oxidative stress results, which can cause significant dam-
age to lipids, proteins, carbohydrates and nucleic acids [9].
Previously, there was found that non-survivor TBI pa-
tient showed higher lipid peroxidation than survivor
patients [10–13]; however, there was also found the ab-
sence of that association [14]. In addition, circulating
TAC in TBI patients has been scarcely studied and only in
studies of small sample size (lower than 55 TBI patients)
[15–17]. In one study were found higher serum TAC in
non-survivor than in survivor TBI patients [15]; however,
an association between circulating TAC and mortality in
patients with TBI has not been previously reported. Thus,
the objective of this study was to determine whether there
is an association between circulating TAC, peroxidation
state and mortality in patients with severe TBI.
Methods
Design and subjects
A prospective, observational, multicenter study was
carried out between 2009–2012 in six Spanish Intensive
Care Units. The study was approved by the Institutional
Review Board of the 6 participating hospitals: Hospital
Universitario de Canarias (La Laguna), Hospital Universi-
tario Nuestra Señora de Candelaria (Santa Cruz de Tener-
ife), Hospital Clínico Universitario de Valencia (Valencia),
Hospital General de La Palma (La Palma), Hospital Uni-
versitario Dr. Negrín (Las Palmas de Gran Canaria), Hos-
pital Insular (Las Palmas de Gran Canaria). Written
informed consent from the legal guardians of the patients
was obtained.
The patient cohort, including 100 patients with severe
TBI, is the same that was used in a previous publication
by our team [13]. Previously we determined malondial-
dehyde (MDA) to assess lipid peroxidation, and at
current study we have analyzed TAC.
We included patients with severe TBI defined as
Glasgow Coma Scale (GCS) lower than 9 points [18].
We excluded patients with age less than 18 years,
pregnancy, inflammatory or malignant disease and
Injury Severity Score (ISS) in non-cranial aspects
higher than 9 points [19].
Variables recorded
The following variables were recorded for each pa-
tient at hospital admission: sex, age, brain lesion ac-
cording to the Marshall computer tomography (CT)
classification [20], ISS, GCS, lactic acid, platelets,
international normalized ratio (INR), activated partial
thromboplastin time (aPTT), fibrinogen, and Acute
Physiology and Chronic Health Evaluation II (APACHE
II) score [21].
End-point
The 30-day mortality was established as endpoint.
Blood sample collection
Blood samples were collected on day 1 of TBI in tubes
with separator gel. After coagulation during 10 min at
room temperature, serum was obtained by centrifugation
at 1000 g for 15 min. The samples were aliquoted and
frozen at −80 °C until determination.
Serum TAC analysis
TAC in serum samples was evaluated using antioxidant
assay kit (Cayman Chemical Corporation, Ann Arbor,
USA). The assay relies on the ability of antioxidants in
the sample to inhibit the oxidation of ABTS® (2,2'-azino-
di-[3-ethylbenzthiazoline sulphonate]) to ABTS®+ by
metmyoglobin. The capacity of the antioxidants in the
sample to prevent ABTS oxidation, is compared with
that of Trolox, a water-soluble tocopherol analogue, and
is quantified as molar Trolox equivalents. All samples
were assayed in duplicate at 20-fold dilutions in assay
buffer following manufacturer’s instructions. Absorbance
at 750 nm was measured using the EnSpire multimode
plate reader (PerkinElmer,Waltham, MA, USA). The
serum concentration of TAC was expressed in mmol/L.
The detection limit of this assay was 0.04 mmol/L; the
intra- and inter-assay CV were 3.4 % and 3.0 %, respect-
ively. To avoid the possible dispersion of serum TAC re-
sults, all the samples were processed at the same time, at
the end of the recruitment process. Serum TAC deter-
mination was performed by a laboratory technician
blinded to all clinical data. TAC assay was performed in
the Genetic Unit of the Instituto de Enfermedades
Tropicales y Salud Pública de Canarias of the University
of the La Laguna (Tenerife, Spain).
Serum MDA analysis
Malondialdehyde (MDA) is an end-product formed dur-
ing this lipid peroxidation, due to degradation of cellular
membrane phospholipids. MDA is released into extra-
cellular space and finally into the blood; and has been
used as an effective biomarker of lipid oxidation [22, 23].
Serum MDA levels were measured using thiobarbituric
acid-reactive substance (TBARS) method as described
by Kikugawa et al. [24]. The pink complex of samples
was extracted in n-butanol. Each sample was placed in a
96-well plate and read at 535 nm in a microplate spectro-
photometer reader (Benchmark Plus, Bio-Rad, Hercules,
CA, USA). The detection limit of this assay was
0.079 nmol/ml; the intra- and inter-assay CV were 1.82 %
and 4.01 %, respectively. The serum concentration of MDA
was expressed in nmol/ml. To avoid the possible dispersion
of serum MDA level results, all the samples were processed
at the same time, at the end of the recruitment process.
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MDA determination was performed by a laboratory techni-
cian blinded to all clinical data. The assay of MDA levels
was centralized in the Department of Physiology, Faculty
of Medicine (University of the La Laguna. Santa Cruz de
Tenerife. Spain).
Statistical methods
Categorical variables are reported as frequencies and per-
centages; and comparisons between groups were carried
out with chi-square test. Continuous variables are re-
ported as medians and interquartile ranges; and compari-
sons between groups were carried out using Wilcoxon-
Mann–Whitney test.
Receiver operating characteristic (ROC) analysis was
carried out to determine the goodness-of-fit of serum
TAC to predict 30-day mortality. Kaplan-Meier analysis
of survival at 30 days and comparisons by log-rank test
were carried out using serum TAC lower/higher than
Table 1 Comparison between survivor and non-survivor TBI patients
Non-survivors Survivors P-
value(n = 27) (n = 73)
Sex female - n (%) 11 (40.7) 12 (16.4) 0.02
Admission abnormal pupils - n (%) 12 (44.4) 11 (15.1) 0.003
Marshall CT classification - n (%) 0.002
Non-evacuated mass lesion 8 (29.6) 3 (4.1)
Evacuated mass lesion 5 (18.5) 26 (35.6)
Type 4 injury 6 (22.2) 10 (13.7)
Type 3 injury 5 (18.5) 13 (17.8)
Type 2 injury 3 (11.1) 21 (28.8)
Type 1 injury 0 0
CT with high risk of death (types 3,4,6) - n (%) 19 (70.4) 26 (35.6 %) 0.003
Age (years) - median (p 25–75) 66 (45–76) 47 (32–67) <0.001
Temperature (°C) - median (p 25–75) 36.0 (35.0–37.0) 37. (35.6–37.3) 0.12
Sodium (mEq/L) - median (p 25–75) 141 (135–149) 139 (138–142) 0.19
Glycemia (g/dL) - median (p 25–75) 161 (142–189) 139 (120–163) 0.08
Leukocytes *103/mm3 - median (p 25–75) 18.3 (10.7–23.9) 14.7 (10.2–19.3) 0.46
PaO2 (mmHg) - median (p 25–75) 141 (104–186) 151 (116–217) 0.34
PaO2/FI02 ratio - median (p 25–75) 190 (154–316) 336 (242–407) 0.11
Bilirubin (mg/dl) - median (p 25–75) 0.75 (0.53–1.05) 0.50 (0.40–0.87) 0.045
Creatinine (mg/dl) - median (p 25–75) 0.95 (0.70–1.10) 0.80 (0.70–0.90) 0.44
Hemoglobin (g/dL) - median (p 25–75) 11.1 (9.4–12.3) 11.4 (10.4–13.0) 0.87
Glasgow Coma Scale score - median (p 25–75) 3 (3–6) 7 (6–8) <0.001
Lactic acid (mmol/L) - median (p 25–75) 1.90 (1.15–4.55) 1.70 (1.23–2.50) 0.16
Platelets *103/mm3 - median (p 25–75) 215 (139–264) 182 (143–252) 0.48
International normalized ratio - median (p 25–75) 1.22 (1.01–1.67) 1.03 (0.92–1.15) 0.15
aPTT (seconds) - median (p 25–75) 26 (25–31) 28 (25–32) 0.86
Fibrinogen (mg/dl) - median (p 25–75) 376 (246–560) 350 (282–444) 0.32
APACHE-II score - median (p 25–75) 26 (25–32) 19 (17–23) <0.001
Injury Severity Score - median (p 25–75) 25 (25–27) 25 (25–32) 0.24
Intracranial pressure (mmHg) - median (p 25–75) 20 (12–30) 15 (14–20) 0.27
Cerebral perfusion pressure (mmHg) - median (p 25-75) 60 (54–69) 68 (57–70) 0.46
Malondialdehyde (nmol/mL) - median (p 25–75) 1.99 (1.31–2.76) 1.35 (1.02–1.79) <0.001
Total antioxidant capacity (nmol/mL) - median (p 25–75) 5.09 (2.78–9.95) 2.31 (1.85–2.84) <0.001
CT Computer tomography, p percentile, PaO2 pressure of arterial oxygen, FIO2 fraction inspired oxygen,
aPTT activated partial thromboplastin time, APACHE II Acute Physiology and Chronic Health Evaluation
* multiplied by
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2.59 nmol/mL as the independent variable and survival
at 30 days as the dependent variable.
Multiple binomial logistic regression analyses were
carried out to determine the association between serum
TAC and 30-day mortality. We constructed three mul-
tiple binomial logistic regression models with only three
predictor variables in each model, due to that the num-
ber of events (death) was 27, to avoid a final model of
order slightly higher than required due to an over fitting
effect. In the first model were included CT with high
risk of death (types 3,4,6), APACHE-II score and serum
TAC > 2.59 nmol/mL. In the second model were in-
cluded age, GCS and serum TAC > 2.59 nmol/mL. In the
third model were included CT with high risk of death
(types 3,4,6), admission abnormal pupils and serum
TAC > 2.59 nmol/mL. Odds Ratio and 95 % confidence
intervals were calculated as measurement of the clinical
impact of the predictor variables. We calculated for each
multiple binomial logistic regression analysis, the overall
predictive capacity to predict 30-day mortality and its
predictive capacity for 30-day mortality (including area
under curve, sensitivity, specificity, positive likelihood
ratio, negative likelihood ratio, positive predicted value,
negative predicted value).
A P value of less than 0.05 was considered statistically
significant. Statistical analyses were performed with
SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and NCSS
2000 (Kaysville, Utah) and LogXact 4.1, (Cytel Co.,
Cambridge, MA).
Results
Comparisons between surviving (N = 73) and non-
surviving (N = 27) patients are shown in Table 1.
Non-surviving TBI patients showed higher rate of fe-
male (p = 0.02). There were statistically significant dif-
ferences in CT classification between non-surviving
and surviving patients (p = 0.002). Non-surviving TBI
patients showed lower GCS (p < 0.001), and higher
age (p < 0.001) and APACHE-II score (p < 0.001) than
survivor ones. In addition, non-surviving patients showed
higher serum TAC (p < 0.001) and MDA (p < 0.001) levels
than surviving ones.
The area under the curve (AUC) for serum TAC as pre-
dictor of 30-day mortality was 0.83 (95 % CI = 0.74-0.90;
P < 0.001) (Fig. 1).
Proportions of non-survivors was higher in patients with
serum TAC higher than 2.59 nmol/mL (21of 48; 43.8 %)
compared with those with lower serum TAC (6 of 52;
11.5 %). For this comparison power analysis was higher
than 95 %.
Survival analysis showed that patients with serum TAC
higher than 2.59 nmol/mL presented higher 30-day mor-
tality than patients with lower levels (Hazard ratio = 4.6;
95 % CI = 2.13–9.76; P < 0.001) (Fig. 2).
Multiple binomial logistic regression analysis showed
that serum TAC higher than 2.59 nmol/mL were associ-
ated with 30-day mortality controlling for APACHE-II
and CT classification (OR = 4.40; 95 % CI = 1.14–16.98;
P = 0.03), controlling for GCS and age (OR = 5.88; 95 %
CI = 1.57–22.06; P = 0.009), and controlling for CT clas-
sification and admission abnormal pupils (OR = 3.89;
95 % CI = 1.30–11.61; P = 0.02) (Table 2). The overall
predictive capacity for the first, second and third multiple
binomial logistic regression analyses to predict 30-day
mortality was 85.4 %, 82.3 % and 76.0 %, respectively. The
area under curve for the first, second and third multiple
binomial logistic regression analyses to predict 30-day
mortality was 0.79, 0.74 and 0.59, respectively (Table 3).
There was an association between serum TAC and
MDA levels (rho = 0.25; p = 0.01), APACHE-II score
(rho = 0.23; p = 0.03) and GCS (rho = −0.21; p = 0.04).
Discussion
To our knowledge, our series is the largest reporting
data on circulating TAC in patients with severe TBI. The
most relevant and new findings of our study were that
there is an association between circulating TAC and per-
oxidation state and mortality in patients with severe TBI.
We found that non-survivor TBI patients showed
higher serum TAC than survivor ones. These findings
are in consonance with those of other previous study of
small sample size [15]. In addition, these findings are
consistent with the results of other studies in septic pa-
tients showing higher circulating TAC in non-survivor
septic patients than in survivor ones [25–27]. A new as-
pect of our study was the association between serum
TAC and mortality in severe TBI patients according to
Fig. 1 Receiver operation characteristic analysis using serum total
antioxidant capacity (TAC) as predictor of mortality at 30 days
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the results of regression analysis. That finding is also in
consonance with the results of other study in septic
patients showing that serum TAC is associated with
mortality in severe septic patients [27]. Besides, we re-
port for the first time that serum TAC could be used to
predict mortality in patients with severe TBI according
the results of ROC curve analysis.
We found a higher rate of death in female than in
male. Previously, there was found a influence of the sex
in the death rate [28, 29]. However, there was found a
worse outcome in females [28], and in males [29]. And
the influence of the hormones was pointed as the pos-
sible explanation for those findings in both cases; thus
the influence and the cause of sex in TBI outcome re-
mains unclear.
Another interesting finding of our study was the asso-
ciation between serum TAC and TBI severity, assessed
by GCS. That finding is in consonance with that of other
previous study of small sample size [16].
We found that non-survivor TBI patients showed
higher serum MDA levels (as biomarker of lipid peroxi-
dation) than survivor ones. That finding is in conson-
ance with the results of other studies showing that non-
survivor TBI patient had higher lipid peroxidation than
survivor patients [10–13]; however, in other series was
not found that association [14].
Fig. 2 Survival curve at 30 days using 2.59 nmol/mL of serum total antioxidant capacity (TAC) as cut-off








CT with high risk of death
(types 3,4,6)
5.22 1.264–21.555 0.02
APACHE-II score 1.14 1.206–1.655 <0.001
Serum TAC > 2.59 nmol/mL 4.40 1.142–16.977 0.03
Second model
Age 1.08 1.033–1.118 <0.001
GCS score 0.54 0.386–0.752 <0.001
Serum TAC > 2.59 nmol/mL 5.88 1.565–22.064 0.009
Third model
CT with high risk of death
(types 3,4,6)
3.84 1.317–11.202 0.01
Admission abnormal pupils 4.06 1.311–12.596 0.02
Serum TAC > 2.59 nmol/mL 3.89 1.301–11.607 0.02
CT Computer tomography, APACHE II Acute Physiology and Chronic Health
Evaluation, TAC Total antioxidant capacity, GCS Glasgow Coma Scale
Table 3 Predictive capacity of the three multiple binomial
logistic regression analysis to predict 30-day mortality
First model Second model Third model
Overall predictive
capacity
85.4 % 82.3 % 76.0 %
Area under curve;
p-value
0.79; p < 0.001 0.74; p < 0.001 0.59; p = 0.03
Sensitivity (95 % CI) 64 (43–82) 56 (35–76) 22 (9–42)
Specificity (95 % CI) 93 (84–98) 92 (83–97) 96 (89–99)
Positive likelihood
ratio (95 % CI)
9.1 (3.7–22.2) 6.6 (2.9–15.4) 5.4 (1.5–20.1)
Negative likelihood
ratio (95 % CI)
0.4 (0.2–0.7) 0.5 (0.3–0.8) 0.8 (0.7–1.0)
Positive predicted
value (95 % CI)
76 (53–92) 70 (46–88) 67 (30–93)
Negative predicted
value (95 % CI)
88 (78–94) 86 (76–93) 77 (67–85)
CI confidence interval
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In addition, other novel aspect of our study was that
there was a positive association between serum TAC and
lipid peroxidation, assessed by serum MDA levels, in se-
vere TBI patients.
We believe that all these findings might suggest that
non-surviving TBI patients with respect to survivor ones
have an increased production of ROS and the increased
TAC attempts to compensate the high production of
oxidant products to maintain the balance between
oxidant and antioxidant state; however, in non-surviving
TBI patients this increased TAC is not enough to com-
pensate the high production of oxidants species and fi-
nally present a high ROS production and high
peroxidation of lipids, proteins, carbohydrates and nucleic
acids. From a therapeutic perspective, the use of antioxi-
dant agents could be used as a new class of drugs for the
treatment of patients with severe TBI according the results
of animal models [30–34].
Finally, some limitations of our study should be recog-
nized. First, the measure of other compounds of oxidant
and antioxidant states would be desirable in order to
better evaluate this balance. Second, we did not perform
the analysis of serum TAC during follow-up. Third, we
did not report data on many patients were excluded
from the study and the motivation for missing. Fourth,
blood samples for serum TAC were collected on the day
of TBI; however, the timing of the blood sampling may
be different among patients due to that the exact mo-
ment of the blood sampling was not reported. Thus,
additional studies are needed to confirm the finding of
our study.
Conclusions
To our knowledge, our series is the largest reporting
data on circulating TAC in patients with severe TBI. The
most relevant and new findings of our study were that
there is an association between circulating TAC and per-
oxidation state and mortality in patients with severe TBI.
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